Lopez-Campos, José Luis
Rapun, Noelia
Czischke, Karen
Jardim, José R.
Acquier, Mariano Fernandez
Munive, Abraham Ali
Günen, Hakan
Drobnic, Estrella
Miravitlles, Marc
Osaba, Lourdes
Funding for this research was provided by:
Grifols (xxx, xxx, xxx)
Article History
Received: 27 December 2022
Accepted: 30 May 2023
First Online: 5 June 2023
Declarations
:
: This study reports the results of a diagnostic procedure that is approved for use in all the participating countries and, therefore, constitutes standard clinical practice. Consequently, since it is not an experimental procedure, approval by an ethics committee was not considered necessary. All patients included signed a written informed consent form.
: Not applicable.
: JLLC has received honoraria during the last 3 years for lecturing, scientific advice, participation in clinical studies or writing for publications for (alphabetical order): AstraZeneca, Bial, Boehringer, Chiesi, CSL Behring, Faes, Ferrer, Gebro, Grifols, GSK, Megalabs, Menarini, Novartis. MM has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Kamada, Takeda, Zambon, CSL Behring, Specialty Therapeutics, Janssen, Grifols and Novartis, consulting fees from AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, CSL Behring, Inhibrx, Ferrer, Menarini, Mereo Biopharma, Spin Therapeutics, ONO Pharma, Palobiofarma SL, Takeda, Novartis, Sanofi and Grifols and research grants from Grifols. LO works as geneticist at Progenika Biopharma, a Grifols Company. ED works in Scientific and Medical Affairs at Grifols.